July 1, 2022

FDA, J&J Near Deal for Covid-19 Vaccine Production at Baltimore Plant

WASHINGTON—The Food and Drug Administration and vaccine maker

Johnson & Johnson

JNJ -0.15%

expect to announce as early as next week that contamination problems at a Covid-19 vaccine plant in Baltimore are resolved, clearing the way for millions more doses to become available.

Vaccine production at the plant run by contract manufacturer

Emergent BioSolutions Inc.

EBS 0.61%

was halted after unsanitary conditions led to contamination of J&J vaccines. The facility made vaccine substance and finished vaccine doses for J&J and


AZN 0.62%


Emergent chief executive

Robert Kramer

told a House committee last week that the company had produced enough of a key ingredient to yield more than 100 million doses of the J&J vaccine.

The company has been taking corrective measures and been in talks with FDA and J&J over the steps needed to reopen the facility.

Johnson & Johnson said it is working with Emergent to secure “as quickly as possible emergency-use-authorization in the U.S. for Covid-19 drug substance manufactured at Emergent Bayview.”

Emergent declined to comment for this article.

The emergency use authorization for the plant to produce Covid-19 vaccine could be made next week, the U.S. officials said. That could help toward fulfilling

President Biden’s

pledges to share 20 million doses from J&J,

Pfizer Inc.

PFE -0.69%


Moderna Inc.

MRNA 2.25%

with the rest of the world by the end of June.

The Baltimore plant has produced millions of doses that were in inventory awaiting authorization, but most aren’t finished and are placed in vials, the officials said, adding it could take months before all those doses are ready for use.

One official said that as part of that arrangement to get the plant online, the U.S. and J&J have tentatively agreed that about 60 million doses of J&J vaccine substance made at the Baltimore plant now will be cleared for use either in the U.S. or overseas.

AstraZeneca is still doing testing on about 60 million doses, also manufactured at the Emergent plant in Baltimore, that could be the subject of another agreement with the FDA in coming weeks or possibly still part of this one, another official said. AstraZeneca declined to comment for this article.

The J&J doses, when they are finished, would be enough to vaccinate about 60 million people with the company’s one-shot regimen. The AstraZeneca doses, if they become available, are a two-dose regimen and could inoculate about half that many people.

An accident at the Baltimore plant led to the contamination of material that could have yielded up to 15 million doses during January and February.

An FDA inspection of the Emergent plant in April concluded that the facility failed to maintain clean and sanitary conditions and didn’t take proper measures to avoid cross-contamination between the two vaccine lines.

Under an agreement with the U.S. government, the U.S. had paid Emergent $271 million of monthly reservation fees to be prepared to manufacture vaccines, but the government partially stopped payment after learning of the contamination, according to a memo from the Democratic staff of the House Select Subcommittee on the Coronavirus Crisis.

At a meeting of the subcommittee last week, Emergent executives blamed some of the problems at its Baltimore vaccine plant on having to produce the two different vaccines simultaneously in large quantities.

Mr. Kramer said that “ramping up production of two novel vaccines on a very large scale in the same facility is unprecedented.”

In an April 30 response to the FDA inspection report, Emergent said it had decommissioned the AstraZeneca portion of its plant in the Bayview section of Baltimore and has taken several steps to avoid any contamination of the J&J vaccine ingredient.

It said it planned to complete several remedial steps, such as repairing, cleaning and disinfecting the manufacturing plant and improving training of personnel at the site.

The company pledged to take several corrective actions during May and June, all of which need to be accomplished before fully recommencing manufacturing at the site.

Write to Thomas M. Burton at [email protected]

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Related Posts

Where Google’s Advertising Chief Searches for Insight

June 12, 2021

June 12, 2021

A week before Lorraine Twohill applied to engineering school in her native Ireland, she found herself reviewing a brochure about...

Rules-Based Redux Unlikely for Fed Communicating Bond Buying Taper

June 16, 2021

June 16, 2021

One of the Federal Reserve’s most consequential challenges over the next few months will be communicating how it will pull...

Apple’s Big Show May Not Be Enough

June 4, 2021

June 4, 2021

As Apple Inc. AAPL 1.81% looks to rally its base, the fate of the company’s lucrative ecosystem has never been...

Costco’s Sales Are Rising but So Are Its Costs

May 27, 2021

May 27, 2021

Costco Wholesale Corp. COST 0.49% said demand surged in its latest quarter as the U.S. economy began to rev up,...

Amazon Founder Jeff Bezos to Be on Blue Origin’s First Human Space Flight

June 7, 2021

June 7, 2021

Jeff Bezos plans to travel to space next month as one of the first passengers carried by Blue Origin, the...

Epic Games Faces Apple in Final Day of Courtroom Battle Over Monopoly Claims

May 24, 2021

May 24, 2021

Lawyers for Apple Inc. AAPL 1.79% and Epic Games Inc. on Monday began making their final arguments to a judge...

Fed’s No. 2 Official Sees Time Approaching for Discussion on Cutting Asset Purchases

May 25, 2021

May 25, 2021

WASHINGTON—A top Federal Reserve official said central bankers may begin discussing a reduction in the central bank’s massive asset purchases...

Fed’s Williams Says Economy Far From Levels Needed to Pare Stimulus

June 3, 2021

June 3, 2021

Federal Reserve Bank of New York leader John Williams said Thursday the U.S. economy remains some distance from where it...

Novavax Covid-19 Vaccine Is 90% Effective in Key Study

June 14, 2021

June 14, 2021

An experimental Covid-19 vaccine from Novavax Inc. was 90.4% effective at preventing symptomatic disease in adults in a large clinical...

Biden Nears Endgame on Fed Chair Decision

November 22, 2021

November 22, 2021

President Biden faces one of the most important economic policy decisions of his presidency, which is expected this week, when...

Google Nears Settlement of Ad-Tech Antitrust Case in France

May 27, 2021

May 27, 2021

Alphabet Inc.’s GOOG -1.27% Google is nearing a settlement of an antitrust case in France alleging the company has abused...

China’s Tech Clampdown Is Spreading

June 6, 2021

June 6, 2021

TAIPEI—The latest salvos in China’s campaign against its tech companies make one thing clear: Jack Ma’s businesses aren’t the only...

Jobs for the City of Tomorrow

June 7, 2021

June 7, 2021

The Future of Everything covers the innovation and technology transforming the way we live, work and play, with monthly issues...

Peugeot Is Latest Auto Maker Charged in French Emissions-Fraud Probe

June 10, 2021

June 10, 2021

PARIS—Peugeot has become the latest auto maker to face preliminary charges in France on suspicion of emissions fraud, extending the...

Apparel Importers, Like Uniqlo, Tripped Up by U.S. Ban on Forced-Labor Goods From China

June 28, 2021

June 28, 2021

WASHINGTON—Surging enforcement by Customs and Border Protection officers of import bans on products made from forced labor is producing disputes...